CD19 and B-cell chronic lymphocytic leukemia: Indeed CD5+CD19+ CLL cells increased in the blood in the presence of ruxolitinib (Figure 2B) and appeared to exit when ruxolitinib was held, associated with changes in chemokines that mediate lymphocyte trafficking (Figure 4).